Stocchi Fabrizio, Tagliati Michele, Olanow C Warren
IRCCS San Raffaele, Via della Pisana 235, Roma, Italy.
Mov Disord. 2008;23 Suppl 3:S599-612. doi: 10.1002/mds.22052.
Chronic levodopa treatment for Parkinson's disease patients is frequently associated with the development of motor complications such as end-of-dose wearing-off and dyskinesias. In this review, we provide an overview of the strategies available for dealing with these problems. Medical management includes manipulation of levodopa dosing to establish the optimum treatment schedule, improving levodopa absorption, catechol-O-methyl transferase-inhibition (COMT), Monoamine oxidase-B (MAO-B) inhibition, dopaminergic agonists, amantadine, and continuous dopaminergic infusions. Surgical procedures and particularly deep brain stimulation are also reviewed. It should be noted that none of these treatments has been shown to provide anti-parkinsonian efficacy that is greater than what can be achieved with levodopa. We highlight the importance of initiating therapy with a treatment strategy that reduces the risk that a Parkinson's disease patient will develop motor complications in the first place. Key Words: Advanced PD, dyskinesias, motor fluctuations, levodopa, dopamine agonists, COMT inhibitors, MAO-B inhibitors.
帕金森病患者长期使用左旋多巴治疗常常会出现运动并发症,如剂末疗效减退和异动症。在本综述中,我们概述了可用于处理这些问题的策略。药物治疗包括调整左旋多巴剂量以制定最佳治疗方案、改善左旋多巴吸收、抑制儿茶酚-O-甲基转移酶(COMT)、抑制单胺氧化酶-B(MAO-B)、使用多巴胺能激动剂、金刚烷胺以及持续多巴胺能输注。我们还综述了手术治疗,尤其是脑深部电刺激。需要注意的是,这些治疗方法均未显示出比左旋多巴更有效的抗帕金森病疗效。我们强调了采用降低帕金森病患者首先出现运动并发症风险的治疗策略启动治疗的重要性。关键词:晚期帕金森病、异动症、运动波动、左旋多巴、多巴胺激动剂、COMT抑制剂、MAO-B抑制剂